Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Evelo Biosciences Inc EVLO

Healthcare Biotechnology
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single... see more

Recent & Breaking News (GREY:EVLO)

Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients

Thomson Reuters ONE May 7, 2020

Evelo Biosciences to Report First Quarter 2020 Financial Results on Monday, May 11, 2020

GlobeNewswire May 4, 2020

Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer

GlobeNewswire April 15, 2020

Evelo Announces Issuance of U.S. Patent Covering Use of Proprietary Bifidobacterium animalis ssp. lactis Strain for Treating Cancer

GlobeNewswire March 5, 2020

Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases

GlobeNewswire March 2, 2020

Evelo Biosciences to Present at 40th Annual Cowen Health Care Conference

GlobeNewswire February 25, 2020

Evelo Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

GlobeNewswire February 13, 2020

Evelo Biosciences to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020

GlobeNewswire February 6, 2020

Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration

GlobeNewswire January 10, 2020

Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

PR Newswire December 19, 2019

Evelo Biosciences Appoints Juan Andres to Board of Directors

GlobeNewswire December 5, 2019

Evelo Biosciences to Present at the Stifel 2019 Healthcare Conference

GlobeNewswire November 13, 2019

Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting

GlobeNewswire November 8, 2019

Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial

GlobeNewswire November 5, 2019

Evelo Biosciences Announces Further Positive Interim Phase 1b Clinical Data in Psoriasis and Reports Third Quarter 2019 Financial Results

GlobeNewswire November 5, 2019

Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, November 5th

GlobeNewswire October 29, 2019

Evelo Biosciences to Present at the 2019 Cantor Global Healthcare Conference

GlobeNewswire September 26, 2019

Evelo Biosciences to Host Key Opinion Leader Symposium on Unmet Need in Mild to Moderate Psoriasis and Potential for EDP1815

GlobeNewswire September 20, 2019

Evelo Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

GlobeNewswire September 3, 2019

Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial

GlobeNewswire August 6, 2019